Posted in | Nanobusiness

Enrollment Begins in Phase 1 Clinical Trial of Novavax’ RSV F-Protein Nanoparticle Vaccine

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy children, the first study of this vaccine candidate to be conducted in a pediatric population.

The trial, which is being conducted in Canada, is a randomized, observer-blinded, dose-ranging Phase 1 study to evaluate the safety and immunogenicity of the RSV F Vaccine, with or without aluminum phosphate adjuvant, in 150 healthy pediatric subjects two to six years of age. In addition to the trial's primary goal of evaluating safety in this population, the study will also evaluate immunogenicity as measured by concentrations of serum IgG antibodies to the RSV fusion, or F-protein, palivizumab-competing antibody titers and RSV microneutralization titers.

"Today's announcement of the initiation of the Phase 1 RSV F Vaccine pediatric trial, delivers on our stated goal of starting RSV F Vaccine trials in all three of our target populations, during the third and fourth quarters of 2014. With the initiation of clinical trials in pregnant women, elderly subjects and children, we position our RSV F Vaccine franchise to deliver important clinical results in the second and third quarter of 2015," said Stanley C. Erck, President and CEO of Novavax.

"RSV is a significant cause of pediatric respiratory disease, including pneumonia, bronchiolitis and recurrent wheezing. The ability to prevent RSV-related lower respiratory disease in the pediatric population via immunization is an important public health goal," said Dr. Gregory Glenn, SVP, Research and Development at Novavax. "We believe this clinical trial is an important step forward in addressing that goal."

Source: http://www.novavax.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Novavax Inc.. (2019, February 11). Enrollment Begins in Phase 1 Clinical Trial of Novavax’ RSV F-Protein Nanoparticle Vaccine. AZoNano. Retrieved on November 12, 2019 from https://www.azonano.com/news.aspx?newsID=31477.

  • MLA

    Novavax Inc.. "Enrollment Begins in Phase 1 Clinical Trial of Novavax’ RSV F-Protein Nanoparticle Vaccine". AZoNano. 12 November 2019. <https://www.azonano.com/news.aspx?newsID=31477>.

  • Chicago

    Novavax Inc.. "Enrollment Begins in Phase 1 Clinical Trial of Novavax’ RSV F-Protein Nanoparticle Vaccine". AZoNano. https://www.azonano.com/news.aspx?newsID=31477. (accessed November 12, 2019).

  • Harvard

    Novavax Inc.. 2019. Enrollment Begins in Phase 1 Clinical Trial of Novavax’ RSV F-Protein Nanoparticle Vaccine. AZoNano, viewed 12 November 2019, https://www.azonano.com/news.aspx?newsID=31477.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit